Search clinical trials for: Hemophilia A, factor VIII, prophylaxis

Total 39783 results

Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
University College, London

Terminated

A Factor IX Gene Therapy Study (FIX-GT) (FIX-GT)

Hemophilia B

Ireland, United Kingdom, Italy, United States
Egymedicalpedia

Completed

Analgesic Effect of Ketamine Vs Ketamine Magnesium Infusion and Their Effect on Postoperative Morphine Consumption

Nephrectomy

Egypt
Cliniques universitaires Saint-Luc- Université...

Completed

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

Hemophilia A

Côte D'Ivoire
Amgen

Completed

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Migraine

United States, Germany, Denmark, Canada, Finland, Sweden, Norway
Amgen

Completed

A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

Migraine

Japan
Investigación en Hemofilia y Fisioterapia

Active, not recruiting

Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia

Hemophilia Arthropathy

Spain
University of Alabama at Birmingham

Completed

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

Lymphoma | Leukemia | Myelofibrosis | Myelodysplastic Syndrome | Severe Aplastic Anemia | Allogeneic Transplant

United States
Prairie Education and Research Cooperative
American College of Phlebology

Terminated

A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis

Deep Vein Thrombosis | Venous Thromboembolism | Coronary Artery Bypass Surgery
Minsk Scientific-Practical Center for Surgery,...
Belarusian State Medical University

Completed

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Multiple Myeloma | Febrile Neutropenia | Pneumococcal Pneumonia | Pneumococcal Infection

Belarus
Brazilian Clinical Research Institute
Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital do Coracao and other collaborators

Terminated

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 (APOLLO)

Covid19 | Thrombosis

Brazil
French National Agency for Research on AIDS and...
Centre Hospitalier Universitaire Dijon; University Hospital, Montpellier; University... and other collaborators

Completed

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

Virus-HIV

France
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Ciceri Fabio

Completed

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (SIR-POSA)

Myelodysplastic Syndromes | Fungal Infection | Graft Vs Host Disease | Leukemia, Acute | Transplant-Related Hematologic Malignancy

Italy
Nantes University Hospital

Terminated

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (CYRIC)

Graft Versus Host Disease

France
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
Pfizer

Completed

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Hemophilia B

India
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
Bloodworks
CSL Behring

Completed

Joint Health Study

Hemophilia B

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Chinese PLA General Hospital
309th Hospital of Chinese People's Liberation Army; Beijing Naval General Hospital and other collaborators

Completed

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

aGVHD

China
Hoffmann-La Roche

Completed

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (POWER)

Haemophilia A | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor | Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor

Italy
University of California, San Diego
Leadiant Biosciences, Inc.

Terminated

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia | Adult Lymphoblastic Lymphoma

United States
McMaster University

Completed

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

Surgery | Venous Thromboembolism | Adherence, Medication | Prophylaxis | Neoplasms Malignant

Canada
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan
Eastern Virginia Medical School
GlaxoSmithKline

Terminated

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

Venous Thromboembolism
Baylor College of Medicine
Shire

Active, not recruiting

Low VW Activity in Adolescent HMB (Low VWF)

Von Willebrand Factor Deficiency

United States
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Science Valley Research Institute
Bayer

Completed

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial (MICHELLE)

Covid19 | Venous Thromboembolism

Brazil
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (ATLAS-INH)

Hemophilia A | Hemophilia B

United States, Australia, Canada, China, France, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, Italy, Japan, South Africa, Spain, Taiwan
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Hemophilia A | Hemophilia B

United States, Australia, China, Denmark, France, Israel, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, South Africa, Spain, Taiwan, Hungary, Italy
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Active, not recruiting

Type 3 Von Willebrand International Registries Inhibitor Prospective Study (3WINTERSIPSEXT)

Type 3 Von Willebrand's Disease

Finland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Fadoi Foundation, Italy
University Of Perugia

Completed

Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. (PRO-LAPSII)

Prevention of Venous Thromboembolism

Italy
Bristol-Myers Squibb
Pfizer

Completed

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Lymphoma | Acute Lymphoblastic Leukemia

United States, Canada, Mexico, Belgium, Russian Federation, Hungary, Korea, Republic of, Australia, Puerto Rico, Czechia, New Zealand, Poland
Shin Mineishi
Milton S. Hershey Medical Center

Withdrawn

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Lymphoma | Leukemia
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

COVID-19

China
Pfizer

Completed

"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

Carcinoma, Renal Cell

Spain
AryoGen Pharmed Co.

Completed

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's Thrombasthenia

Iran, Islamic Republic of
Meir Medical Center

Completed

Anti-factor Xa Based Venous Thromboembolism Prophylaxis

Dose Adjustment of Enoxaparin in ICU Patients

Israel
University Hospital, Montpellier

Completed

Screening for Bleeding Disorders in Children

Bleeding Disorder

France
University of Toronto

Completed

Comic Intervention for Sexual Violence Prevention and Post-rape Care

Knowledge, Attitudes, Practice | Post-exposure Prophylaxis

Canada, Uganda
Novartis Pharmaceuticals

Completed

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Heart Failure

United States
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

United States, United Kingdom, Taiwan, Italy, Spain, India, Turkey, Malaysia, Russian Federation, Armenia, Georgia, Hungary, Mexico, Poland, South Africa, Ukraine

Search clinical trials for: Hemophilia A, factor VIII, prophylaxis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations